FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
ID: FDABAA-24-00123_AwardType: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA Office of Acquisitions and Grants ServicesRockville, MD, 20857, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH (AJ11)

Original Source

https://sam.gov/opp/2d8727abeb8541688a9f24eda6852615/view
Timeline
    Description

    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.

    Point(s) of Contact
    Ian Weiss
    (301) 796-5728
    Ian.Weiss@fda.hhs.gov
    Files
    Title
    Posted
    BAA_AwardedFY24.pdf
    The government file details awarded contracts from various agencies, primarily focused on health, medical, and regulatory research. It lists multiple awards, including the contract number, obligated amount, and recipient information. Key projects include the development of endpoints for atopic dermatitis, interactive lab-test driven discovery engines, and methodologies for assessing opioid exposure in pediatric populations. Awardees such as academic institutions and private companies are allocated significant funding, indicating federal investment in cutting-edge health research and technology. Notably, the contracts span diverse topics from real-world evidence for drug safety to advancements in gene therapy. The total obligated amount for these contracts exceeds $24 million, reflecting a strategic emphasis on innovation and patient engagement within the healthcare sector. Overall, the document illustrates the federal government's commitment to fostering research initiatives that enhance healthcare delivery and regulatory processes.
    BAAwardedFY24.pdf
    The document outlines a series of federal contracts awarded primarily for research projects under the Center for Drug Evaluation and Research (CDER) and other agencies. It lists various awards, detailing their contract numbers, obligated amounts, total estimated values, awardee names and addresses, and project titles. The contracts cover diverse topics, such as developing therapeutic tools for T cell assays, reviewing opioid impact on pediatric populations, and enhancing regulatory decision-making through real-world data analysis. The total amount obligated across all contracts is approximately $20.6 million, with the estimated total value exceeding $31 million. These projects reflect the government's focus on improving public health and regulatory processes through innovative research, emphasizing collaboration with academic institutions and organizations to address pressing health issues. The data illustrates the government's ongoing commitment to advancing medical research and ensuring the safety and efficacy of drugs and devices through funding and support.
    Similar Opportunities
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is soliciting proposals for the FY25 Broad Agency Announcement (BAA) aimed at advancing research and development in regulatory science. This initiative seeks to acquire innovative research proposals that enhance the FDA's mission to protect public health by modernizing the evaluation of FDA-regulated products and improving post-market surveillance. Eligible applicants, including private organizations and academic institutions, are encouraged to submit proposals that address critical knowledge gaps and align with FDA priorities, with a submission deadline for full proposals set for February 24, 2025. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Business Data Enrichment Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking information on Business Data Enrichment Services to support the establishment of an enterprise master data management program. The primary objective is to enhance the accuracy and completeness of business data across operational and analytical systems, which is crucial for regulatory compliance and public health initiatives. This Request for Information (RFI) is part of the FDA's efforts to gather insights from the marketplace regarding potential solutions and capabilities, particularly in light of legislative requirements such as the Drug Supply Chain and Security Act. Interested stakeholders must submit their responses by November 15, 2024, and can direct inquiries to Noah Padilla at Noah.Padilla@fda.hhs.gov or Peter Lee at peter.lee@fda.hhs.gov.
    Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation, aimed at enhancing decentralized healthcare services and clinical trial capabilities. This initiative invites partnerships with organizations such as retail pharmacies, telemedicine providers, and Clinical Research Organizations (CROs) to develop sustainable infrastructures for conducting decentralized clinical trials, particularly in response to public health emergencies. The program emphasizes the importance of innovative approaches to medical countermeasure development and aims to address challenges in decentralized trial implementation while ensuring diverse participant representation. Interested parties must submit their proposals by December 9, 2024, at 12:00 PM EST, with an anticipated funding amount of up to $100 million distributed over a five-year performance period. For inquiries, contact William K. Hunter at LaunchOfficeContracting@hhs.gov.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    Solicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) is seeking proposals for various health research and development services. This opportunity is typically used for experimental development and healthcare services. The place of performance is in the USA. For more information, please contact BARDA-BAA@hhs.gov. The deadline for proposal submission is September 25, 2028, at 4:30 PM Eastern Time.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including vaccine innovation, digital health technologies, and therapeutics for acute radiation syndrome, with specific deadlines for each AOI ranging from March 15, 2024, to January 20, 2025. This opportunity is crucial for advancing biomedical research and developing effective responses to health emergencies, and interested parties must register on SAM.gov and submit their abstracts by the specified deadlines. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, manufacture, and distribute a variety of drug compounds, including controlled substances, to support drug abuse and addiction research. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement, is expected to span five years and will allow for both cost reimbursement and fixed-price task orders based on NIDA's needs. Interested offerors must submit their proposals electronically by November 15, 2024, and ensure compliance with federal acquisition regulations, including maintaining active registration in the System for Award Management (SAM). For further inquiries, potential bidders can contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov.
    Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic. This initiative aims to enhance access to clinically validated curative cell therapies for pediatric patients with rare genetic diseases by advancing novel quality assurance mechanisms at Academic Medical Centers. The program focuses on developing innovative solutions for small-batch manufacturing of autologous cell therapies, addressing production variability, regulatory approval barriers, and ensuring product quality. Proposals are due by November 18, 2024, at 12 PM EST, with the final solicitation released on October 22, 2024. Interested parties should direct inquiries to the designated contact email provided in the solicitation documents.
    FY25 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology
    Active
    Dept Of Defense
    The Department of Defense, through the Office of Naval Research, is soliciting proposals for the FY25 Long Range Broad Agency Announcement (BAA) aimed at advancing Navy and Marine Corps science and technology initiatives. This opportunity invites submissions from a diverse range of sources, including academia, industry, and the research community, to support long-range science and technology projects that enhance operational capabilities. The BAA emphasizes the importance of competitive funding for innovative research across various science and engineering disciplines, encouraging participation from both small and large businesses. Interested parties can reach out to Christine Williams at christine.m.williams2.civ@us.navy.mil for further details regarding proposal submissions and funding considerations.
    Request for Information: Literature Search and Summarization Tools
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking information on literature search and summarization tools to enhance drug safety research. The FDA aims to identify commercial tools that utilize artificial intelligence, particularly natural language processing (NLP), to assist in the classification, summarization, and extraction of relevant medical literature, addressing challenges in evaluating adverse drug reactions. This Request for Information (RFI) is part of a market research initiative and does not constitute a solicitation for contracts; interested parties are encouraged to submit their responses by the specified deadline to Ian Weiss at ian.weiss@fda.hhs.gov, with a focus on the tool's capabilities, interoperability, and validation methods.
    Office-Wide Innovative Solutions Opening for Health Science Futures (HSF)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) aimed at advancing healthcare technologies. This initiative seeks innovative, disease-agnostic research projects that can significantly improve health outcomes, focusing on areas such as maternal and fetal health, genetic therapies, and novel diagnostic tools. The solicitation emphasizes the development of transformative solutions rather than incremental research, with submissions required to follow a two-step process: an initial solution summary followed by a full proposal based on feedback received. Interested parties must submit their solution summaries by March 3, 2029, via the designated ARPA-H portal, and are encouraged to review the detailed submission guidelines outlined in the provided documentation.